---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-335267"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2025-12-29T23:59:59+00:00"
generated_at: "2026-05-16T12:08:00.280706+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics establishes new $75M ATM equity program via UBS, terminates prior $20M ATM

## Summary
- Entered sales agreement with UBS Securities for at-the-market offering of common stock up to $75 million aggregate offering price.
- Prior $20M ATM program with Cantor Fitzgerald terminated effective Dec 17, 2025; Cantor waived 60-day restriction.
- Net proceeds intended for pipeline development, general corporate and working capital purposes.
- Agent fee up to 3% of gross proceeds; program may be terminated by either party on 10 days' notice.

## SEC filing metadata
- accession: 0001193125-25-335267
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2025-12-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000119312525335267/0001193125-25-335267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000119312525335267/sabs-20251229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-335267
- JSON: https://secwatch.observer/filing/0001193125-25-335267.json
- Plain text: https://secwatch.observer/filing/0001193125-25-335267.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.